Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Abstract:

:Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years. Single-dose experimental studies have shown benzbromarone to have a urate-lowering effect similar to that of a therapeutic dose of probenecid or sulphinpyrazone, but unlike these drugs benzbromarone can be administered in a once daily regimen. In 2 short-term comparative therapeutic trials in a small number of patients with hyperuricaemia, 80mg of micronised benzbromarone daily was at least as effective as 1000mg of probenecid or 300mg of allopurinol daily in lowering serum uric acid levels. Side-effects during benzbromarone administration are usually mild and primarily gastrointestinal in nature.

journal_name

Drugs

journal_title

Drugs

authors

Heel RC,Brogden RN,Speight TM,Avery GS

doi

10.2165/00003495-197714050-00002

subject

Has Abstract

pub_date

1977-11-01 00:00:00

pages

349-66

issue

5

eissn

0012-6667

issn

1179-1950

journal_volume

14

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Coronary thrombolysis for evolving myocardial infarction.

    abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428050-00004

    authors: Spann JF,Sherry S

    更新日期:1984-11-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • The diuretic dilemma and the management of mild hypertension.

    abstract::Diuretics are used in first-step antihypertensive monotherapy or in combination with adrenergic-inhibiting agents in the majority of hypertensive patients in the United States. A 30-year experience has demonstrated that blood pressure is lowered to as great or greater a degree with diuretics than when many of the pres...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600314-00007

    authors: Moser M

    更新日期:1986-01-01 00:00:00

  • Peramivir: A Review in Uncomplicated Influenza.

    abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0981-8

    authors: Scott LJ

    更新日期:2018-09-01 00:00:00

  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767001-00005

    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

    abstract::Gastro-oesophageal reflux disease (GORD or GERD) is a very common disorder, and advancement in drug development over the years has markedly improved disease management. Proton pump inhibitors (PPIs) remain the mainstay of treatment for GERD due to their profound and consistent inhibitory effect on acid secretion. Howe...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11597300-000000000-00000

    authors: Hershcovici T,Fass R

    更新日期:2011-12-24 00:00:00

  • Panobinostat: first global approval.

    abstract::Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0388-8

    authors: Garnock-Jones KP

    更新日期:2015-04-01 00:00:00

  • The role of vasodilator therapy in the treatment of severe chronic heart failure.

    abstract::The rationale for the use of vasodilating agents in the treatment of congestive heart failure is to reverse the systemic vasoconstriction that characterises patients with this disorder, and which may further limit cardiac performance. Nitrates were the first vasodilators used, followed by arterial vasodilators (hydral...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600325-00003

    authors: Packer M

    更新日期:1986-01-01 00:00:00

  • Lumasiran: First Approval.

    abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01463-0

    authors: Scott LJ,Keam SJ

    更新日期:2021-01-06 00:00:00

  • Olaratumab: First Global Approval.

    abstract::Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0680-2

    authors: Shirley M

    更新日期:2017-01-01 00:00:00

  • Current use and future potential role of retinoids in dermatology.

    abstract::Since their introduction 15 years ago, retinoids have been increasingly used for topical and systemic treatment of psoriasis and other hyperkeratotic and parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related dermatoses, and also for therapy and/or chemoprevention of skin cancer and other...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753030-00003

    authors: Orfanos CE,Zouboulis CC,Almond-Roesler B,Geilen CC

    更新日期:1997-03-01 00:00:00

  • Corticosteroids and adrenal suppression. Characterising and avoiding the problem.

    abstract::Glucocorticoids are used for a variety of illnesses. One of their major complications is suppression of the hypothalamic-pituitary-adrenal axis, rendering a patient unable to respond to stress. The risk of this suppression may be minimised by the use of short-acting glucocorticoid preparations, administration of the e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938050-00008

    authors: Helfer EL,Rose LI

    更新日期:1989-11-01 00:00:00

  • Pharmacological and biochemical actions of sulphasalazine.

    abstract::This review considers recent pharmacological and biochemical studies of sulphasalazine and its colonic metabolites, 5-aminosalicylic acid and sulphapyridine, in relation to the use of the parent drug for the treatment of ulcerative colitis and, more recently, rheumatoid arthritis. Several factors make it difficult to ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198600321-00005

    authors: Hoult JR

    更新日期:1986-01-01 00:00:00

  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • Antidepressants for the treatment of insomnia : a suitable approach?

    abstract::The popularity of antidepressants in the treatment of insomnia is not supported by a large amount of convincing data, but rather by opinions and beliefs of the prescribing physicians on the advantages of these agents compared with drugs acting on the benzodiazepine receptor or other drugs used for the treatment of ins...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/0003495-200868170-00001

    authors: Wiegand MH

    更新日期:2008-01-01 00:00:00

  • Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

    abstract::Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767050-00003

    authors: Jost WH,Blümel J,Grafe S

    更新日期:2007-01-01 00:00:00

  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

    abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11317670-000000000-00000

    authors: Morse MA,Todd JW,Stouffer GA

    更新日期:2009-10-01 00:00:00

  • Practical treatment guide for dose individualisation in cancer chemotherapy.

    abstract::Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this parameter. Consequently, following administration of equivalent drug dosages based...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856060-00006

    authors: Canal P,Chatelut E,Guichard S

    更新日期:1998-12-01 00:00:00

  • Etanercept: a review of its use in autoimmune inflammatory diseases.

    abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0258-9

    authors: Scott LJ

    更新日期:2014-08-01 00:00:00

  • Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.

    abstract::Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or m...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01456-z

    authors: Rathi N,McFarland TR,Nussenzveig R,Agarwal N,Swami U

    更新日期:2020-12-28 00:00:00

  • Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.

    abstract::Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia, and cardiac toxicity. The role of anthracycline-containing regimens...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300452-00007

    authors: Fumoleau P,Devaux Y,Vo Van ML,Kerbrat P,Fargeot P,Schraub S,Mihura J,Namer M,Mercier M

    更新日期:1993-01-01 00:00:00

  • Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

    abstract::Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510040-00001

    authors: Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

    更新日期:1975-01-01 00:00:00

  • The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.

    abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00011

    authors: Lassman HB,Ho I,Puri SK,Sabo R,Scheffler MR

    更新日期:1988-01-01 00:00:00

  • Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

    abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-018-1009-0

    authors: Chen BK,Yang YT,Bennett CL

    更新日期:2018-11-01 00:00:00

  • Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

    abstract::The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198734030-00004

    authors: Sandström EG,Kaplan JC

    更新日期:1987-09-01 00:00:00

  • Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and all...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198427030-00003

    authors: Richards DM,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1984-03-01 00:00:00

  • Statins and pregnancy: between supposed risks and theoretical benefits.

    abstract::Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632010-000000000-00000

    authors: Lecarpentier E,Morel O,Fournier T,Elefant E,Chavatte-Palmer P,Tsatsaris V

    更新日期:2012-04-16 00:00:00

  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis

    abstract:BACKGROUND:The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/00003495-200464002-00005

    authors: Sever PS,Dahlöf B,Poulter NR,Wedel H,Beevers G,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,Ostergren J,ASCOT Investigators.

    更新日期:2004-01-01 00:00:00

  • Platelets, thrombosis and drugs.

    abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197509010-00003

    authors: Mustard JF,Packham MA

    更新日期:1975-01-01 00:00:00